New devices in heart failure: An European Heart Rhythm Association report

Europace

Volumn 16, Issue 1, 2014, Pages 109-128

  Kuck, Karl Heinz ^a   Bordachar, Pierre ^a   Borggrefe, Martin ^a   Boriani, Giuseppe ^a   Burri, Haran ^a   Leyva, Francisco ^a   Schauerte, Patrick ^a   Theuns, Dominic ^a   Thibault, Bernard ^a   Kirchhof, Paulus ^a   Hasenfuss, Gerhard ^a   Dickstein, Kenneth ^a   Leclercq, Christophe ^a   Linde, Cecilia ^a   Tavazzi, Luigi ^a   Ruschitzka, Frank ^a  

^a NONE

Author keywords

Cardiac contractility modulation; Heart failure devices; Narrow QRS complex; Pressure monitoring

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CARDIAC CONTRACTILITY MODULATION; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR THERAPEUTIC DEVICE; CAROTID SINUS NERVE STIMULATION; CAROTID SINUS NERVE STIMULATOR; CERVICAL VAGAL STIMULATION; CLINICAL EVALUATION; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DEVICE SAFETY; ELECTROSTIMULATION; EXERCISE TOLERANCE; FOLLOW UP; HEART FAILURE; HEART LEFT ATRIUM PRESSURE; HEART MUSCLE OXYGEN CONSUMPTION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; IMPLANTABLE HEMODYNAMIC MONITOR; IMPLANTABLE HEMODYNAMIC MONITORING DEVICE; INTRACARDIACATRIOVENTRICULAR NODAL VAGAL STIMULATION; LUNG ARTERY PRESSURE; META ANALYSIS; MULTICENTER STUDY (TOPIC); NEUROMODULATION; NEW YORK HEART ASSOCIATION CLASS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QRS COMPLEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL CORD STIMULATION DEVICE; THERAPY EFFECT; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

CARDIAC CONTRACTILITY MODULATION; HEART FAILURE DEVICES; NARROW QRS COMPLEX; PRESSURE MONITORING;

BLOOD PRESSURE DETERMINATION; EQUIPMENT DESIGN; EUROPE; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; PACEMAKER, ARTIFICIAL; SPINAL CORD STIMULATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL; THERAPY, COMPUTER-ASSISTED; VAGUS NERVE STIMULATION;

EID: 84891367468     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut311     Document Type: Article

References (180)

1. Dickstein K et al.; ESC Committee for Practice Guidelines. 2010 Focused Update of ESC Guidelinesondevice therapyinheart failure:anupdateofthe 2008 ESC Guidelines for the diagnosis and treatmentof acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace 2010;12:1526-36.
2. Daubert JC et al. EHRA/HRS expert consensus statement on cardiac resynchroni-zation therapy in heart failure: implant and follow-up recommendations and management. Europace 2012;14:1236-86.
3. Brignole M et al. ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15: 1070-118.
4. Abraham WT et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 2002;346:1845-53.
5. Bristow MR et al. Cardiac-resynchronization therapy with or without an implanta-ble defibrillator inadvanced chronic heart failure. N Engl J Med 2004;350:2140-50.
6. Beshai JF et al. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med 2007.
7. Lund LH et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 2013; 34:529-39.
8. Shenkman HJet al. Congestiveheart failure and QRS duration: establishing prognosis study. Chest 2002;122:528-34.
9. Maggioni APet al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010;12:1076-84.
10. McMurray JJ et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2010 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
11. Burkhoff D et al. Nonexcitatory electrical signals for enhancing ventricular contractility: rationale and initial investigations of an experimental treatment for heart failure. Am J Physiol Heart Circ Physiol 2005;288:H2550-6.
12. Lawo T et al. Electrical signals applied during the absolute refractory period: an in-vestigational treatment for advanced heart failureinpatients with normal QRS duration. J Am Coll Cardiol 2005;46:2229-36.
13. Sabbah HN et al. Cardiac contractilty modulation with the impulsedynamics signal: studies in dogs with chronic heart failure. Heart Fail Rev 2001;6:45-53.
14. Mohri S et al. Cardiac contractility modulation by electric currents applied during the refractory period. Am J Physiol Heart Circ Physiol 2002;282:H1642-7.
15. Morita H et al. Cardiac contractility modulation with nonexcitatory electric signals improves left ventricular function indogs with chronic heart failure.J Card Fail 2003; 9:69-75.
16. Imai M et al. Therapy with cardiac contractility modulation electrical signals improves left ventricular function and remodeling in dogs with chronic heart failure. J Am Coll Cardiol 2007;49:2120-8.
17. Pappone C et al. Cardiac contractility modulation by electric currents applied during the refractory period in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002;90:1307-13.
18. Pappone C et al. Electrical modulation of cardiac contractility: clinical aspects in congestive heart failure. Heart Fail Rev 2001;6:55-60.
19. Butter C et al. Enhanced inotropic state of the failing left ventricle by cardiac contractility modulation electrical signals is not associated with increased myocardial oxygen consumption. J Card Fail 2007;13:137-42.
20. Nelson GS et al. Left ventricularorbiventricular pacingimproves cardiac functionat diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block [In Process Citation]. Circulation (Online) 2000;102:3053-9.
21. Pappone C et al. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study. J Cardiovasc Electro-physiol 2004;15:418-27.
22. Yu CM et al. Impactofcardiac contractility modulationon left ventricular global and regional function and remodeling. JACC Cardiovasc Imaging 2009;2:1341-9.
23. Blank M et al. Initial interactions inelectromagnetic field-induced biosynthesis. J Cell Physiol 2004;199:359-63.
24. Butter C et al. Cardiac contractility modulation electrical signals improve myocar-dial gene expressioninpatients with heart failure. J Am Coll Cardiol 2008;51:1784-9.
25. Stix G et al. Chronic electrical stimulation during the absolute refractory period of the myocardium improves severe heart failure. Eur Heart J 2004;25:650-5.
26. Neelagaru SB et al. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm 2006;3:1140-7.
27. Borggrefe MM et al. Randomized, double blind studyofnon-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008;29:1019-28.
28. Kadish A et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011;161: 329-37.
29. Burkhoff D et al. 'Responder analysis' for assessing effectiveness of heart failure therapies based on measures of exercise tolerance. J Card Fail 2009;15:108-15.
30. Abraham WT et al. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail 2011;17:710-7.
31. Schau T et al. Long-term outcome of cardiac contractility modulation in patients with severe congestive heart failure. Europace 2011;13:1436-44.
32. Nägele H et al. Cardiac contractility modulation in non-responders to cardiac resynchronization therapy. Europace 2008;10:1375-80.
33. Binkley PF et al. Parasympathetic withdrawalisan integral componentofautonomic imbalance in congestive heart failure: demonstration in human subjects and verification in a paced canine model of ventricular failure. J Am Coll Cardiol 1991;18: 464-72.
34. Rydlewska A et al. Changes in autonomic balance in patients with decompensated chronic heart failure. Clin Auton Res 2011;21:47-54.
35. Schwartz PJ et al. Sympathetic-parasympathetic interaction in health and disease: abnormalities and relevance in heart failure. Heart Fail Rev 2011;16:101-7.
36. La Rovere MT et al.; ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 1998;351:478-84.
37. Cygankiewicz I et al.; Muerte Subita en Insuficiencia Cardiaca Investigators. Heart rate turbulence predicts all-cause mortality and sudden death in congestive heart failure patients. Heart Rhythm 2008;5:1095-102.
38. Foody JM et al. Beta-blocker therapy in heart failure: scientific review. JAMA 2002; 287:883-9.
39. Mendelowitz D. Firing properties of identified parasympathetic cardiac neurons in the nucleus ambiguus. Am J Physiol 1996;271:H2609-14.
40. Wang J et al. Synaptic and neurotransmitter activation of cardiac vagal neurons in the nucleus ambiguus. Ann N Y Acad Sci 2001;940:237-46.
41. Olgin JE et al. Effects of thoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol 2002; 13:475-81.
42. Jesus S et al. Initial experience with spinal cord stimulation (SCS) for the treatment of advanced heart failure. J Card Fail 2010;16:S67.
43. Long DM et al. Electrical stimulation of the spinal cord and peripheral nerves for pain control. A 10-year experience. Appl Neurophysiol 1981;44:207-17.
44. Mannheimer C et al. The problem of chronic refractory angina; report from the esc joint study group on the treatment of refractory angina. Eur Heart J 2002;23: 355-70.
45. de Jongste MJ et al. Stimulation characteristics, complications, and efficacy of spinal cord stimulation systemsin patients with refractory angina: a prospective feasibility study. Pacing Clin Electrophysiol 1994;17:1751-60.
46. Hautvast RW et al. Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. Am Heart J 1998;136:1114-20.
47. Brodison A et al. Spinal-cord stimulation inmanagementofangina. Lancet 1999;354: 1748-9.
48. de Vries J et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the spirit trial. Eur Heart J 2006;27:1631-2; author reply 1632.
49. Eliasson T et al. Spinal cord stimulation in angina pectoris with normal coronary arteriograms. Coron Artery Dis 1993;4:819-27.
50. Lanza GA et al. Effect of spinal cord stimulationon spontaneous and stress-induced angina and 'ischemia-like' ST-segment depression in patients with cardiac syndrome X. Eur Heart J 2005;26:983-9.
51. Ubbink DT et al. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev 2005;CD004001.
52. Klomp HM et al. Systematic review and meta-analysis of controlled trials assessing spinal cord stimulation for inoperable critical leg ischaemia (Br J Surg 2004;91:948-955). Br J Surg 2005;92:120; author reply 120-121.
53. Sibell DM et al. Successful use of spinal cord stimulation in the treatment of severe Raynaud's disease of the hands. Anesthesiology 2005;102:225-7.
54. Hosobuchi Y. Electrical stimulation of the cervical spinal cord increases cerebral blood flow in humans. Appl Neurophysiol 1985;48:372-6.
55. Visocchi M et al. Spinal cord stimulation and cerebral hemodynamics: updated mechanism and therapeutic implications. Stereotact Funct Neurosurg 2011;89: 263-74.
56. Latif OA et al. Spinal cord stimulation for chronic intractable angina pectoris: a unified theory on its mechanism. Clin Cardiol 2001;24:533-41.
57. McNab D et al. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the spirit trial. Eur Heart J 2006;27:1048-53.
58. Melzack R et al. Pain mechanisms: a new theory. Science 1965;150:971-9.
59. Wu M et al. Putative mechanisms behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. Auton Neurosci 2008;138:9-23.
60. Chandler MJ et al. A mechanism of cardiac pain suppression by spinal cord stimulation: implications for patients with angina pectoris. Eur Heart J 1993;14:96-105.
61. Hautvast RW et al. Effect of spinal cord stimulation on heart rate variability and myocardial ischemia in patients with chronic intractable angina pectoris-a prospective ambulatory electrocardiographic study. Clin Cardiol 1998;21:33-8.
62. Diedrichs H et al. [Increased myocardial blood flow after spinal cord stimulation in patients with refractory angina pectoris]. Med Klin (Munich) 2003;98:146-50.
63. Diedrichs H et al. Symptomatic relief precedes improvement of myocardial blood flow in patients under spinal cord stimulation. Curr Control Trials Cardiovasc Med 2005;6:7.
64. Olshansky B et al. Parasympathetic nervous system and heart failure: pathophysi-ology and potential implications for therapy. Circulation 2008;118:863-71.
65. Ardell JL et al. Dorsal spinal cord stimulation obtunds the capacity of intrathoracic extracardiac neurons to transduce myocardial ischemia. Am J Physiol Regul Integr Comp Physiol 2009;297:R470-77.
66. Armour JA et al. Long-term modulation of the intrinsic cardiac nervous system by spinal cord neurons in normal and ischaemic hearts. Auton Neurosci 2002;95:71-9.
67. Cardinal R et al. Spinal cord activation differentially modulates ischaemic electrical responses to different stressors in canine ventricles. Auton Neurosci 2004;111: 37-47.
68. Cardinal R et al. Spinal cord stimulation suppresses bradycardias and atrial tachyar-rhythmias induced by mediastinal nerve stimulation in dogs. Am J Physiol Regul Integr Comp Physiol 2006;291:R1369-75.
69. Foreman RD et al. Modulation of intrinsic cardiac neurons by spinal cord stimulation: Implications for its therapeutic use in angina pectoris. Cardiovasc Res 2000; 47:367-75.
70. Gibbons DD et al. Neuromodulation targets intrinsic cardiac neurons to attenuate neuronally mediated atrial arrhythmias. Am J Physiol Regul Integr Comp Physiol 2012; 302:R357-64.
71. Jacques F et al. Spinal cord stimulation causes potentiation of right vagus nerve effects on atrial chronotropic function and repolarization in canines. J Cardiovasc Electrophysiol 2011;22:440-7.
72. Southerland EM et al. Preemptive, but not reactive, spinal cord stimulation mitigates transient ischemia-induced myocardial infarction via cardiac adrenergic neurons. Am J Physiol Heart Circ Physiol 2007;292:H311-7.
73. Binkley PF et al. A polymorphism of the endothelial nitric oxide synthase promoter is associated with an increase in autonomic imbalance in patients with congestive heart failure. Am Heart J 2005;149:342-8.
74. Markos F et al. Nitric oxide facilitates vagal control of heart rate via actions in the cardiac parasympathetic ganglia of the anaesthetised dog. Exp Physiol 2002;87: 49-52.
75. Li W et al. Inflammatory cytokines and nitric oxide in heart failure and potential modulation by vagus nerve stimulation. Heart Fail Rev 2011;16:137-45.
76. Eliasson T et al. Myocardial turnover of endogenous opioids and calcitonin-gene-related peptide in the human heart and the effects of spinal cord stimulation on pacing-induced angina pectoris. Cardiology 1998;89:170-7.
77. Kujacic V et al. Assessment of the influence of spinal cord stimulation on left ventricular function in patients with severe angina pectoris: an echocardiographic study. Eur Heart J 1993;14:1238-44.
78. Gersbach PA et al. Spinal cord stimulation treatment for angina pectoris: more than a placebo? Ann Thorac Surg 2001;72:S1100-04.
79. Issa ZF et al. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmias in a postinfarction heart failure canine model. Circulation 2005;111: 3217-20.
80. Lopshire JC et al. Spinal cord stimulation improves ventricular function and reduces ventricular arrhythmias in a canine postinfarction heart failure model. Circulation 2009;120:286-94.
81. Liu Y et al. Thoracic spinal cord stimulation improves cardiac contractile function and myocardial oxygen consumption in a porcine model of ischemic heart failure. J Cardiovasc Electrophysiol 2011.
82. Henderson JM et al. Nans training requirements for spinal cord stimulation devices: selection, implantation, and follow-up. Neuromodulation 2009;12:171-4.
83. Brook AL et al. Spinal cord stimulation: a basic approach. Tech Vasc Interv Radiol 2009;12:64-70.
84. Hegarty D. Spinal cord stimulation: the clinical application of new technology. Anesthesiol Res Pract 2012;2012:375691.
85. Bedder MD et al. Spinal cord stimulation surgical technique for the nonsurgically trained. Neuromodulation 2009;12(Suppl 1):1-19.
86. Reig E et al. Spinal cord stimulation: a20-year retrospective analysis in 260 patients. Neuromodulation 2009;12:232-9.
87. Mekhail NA et al. Retrospective review of 707 cases ofspinal cord stimulation: indications and complications. Pain Pract 2011;11:148-53.
88. Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review. J Neurosurg 2004;100:254-67.
89. Romano M et al. Efficacy and safetyofpermanent cardiac DDD pacingwith contemporaneous double spinal cord stimulation. Pacing Clin Electrophysiol 1998;21:465-7.
90. Ekre O et al. Feasibility of spinal cord stimulation in angina pectoris in patients with chronic pacemaker treatment for cardiac arrhythmias. Pacing Clin Electrophysiol 2003;26:2134-41.
91. Schimpf R et al. Potential device interaction of a dual chamber implantable cardio-verter defibrillator in a patient with continuous spinal cord stimulation. Europace 2003;5:397-402.
92. Kosharskyy B et al. Feasibility of spinal cord stimulation in a patient with a cardiac pacemaker. Pain Physician 2006;9:249-51.
93. Ferrero P et al. Spinal cord stimulation affects T-wave alternans in patients with is-chaemic cardiomyopathy: a pilot study. Europace 2008;10:506-8.
94. Enggaard TP et al. Spinal cord stimulation for refractory anginainpatients implanted with cardioverter defibrillators: five case reports. Europace 2010;12:1336-7.
95. Molon G et al. ICD and neuromodulation devices: is peaceful coexistence possible? Pacing Clin Electrophysiol 2011;34:690-3.
96. Ooi YC et al. Simultaneous use of neurostimulators in patients with a preexisting cardiovascular implantable electronic device. Neuromodulation 2011;14:20-5; discussion 25-26.
97. Kirchheim HR. Systemic arterial baroreceptor reflexes. Physiol Rev 1976;56: 100-77.
98. Czachurski J et al. Localization of neurons with baroreceptor input in the medial solitary nucleus by means of intracellular application of horseradish peroxidase in the cat. Neurosci Lett 1982;28:133-7.
99. Andresen MC et al. Nucleus tractussolitarius-gateway to neural circulatory control. Annu Rev Physiol 1994;56:93-116.
100. Kollai M et al. Relation between baroreflex sensitivity and cardiac vagal tone in humans. Am J Physiol 1994;266(Pt 2):H21-7.
101. Eckberg DL et al. Defective cardiac parasympathetic control in patients with heart failure. N Engl J Med 1971;285:877-83.
102. Bristow MR et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 1982;307:205-11.
103. Brunner-La Rocca HP et al. Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. Eur Heart J 2001;22:1136-43.
104. Creager MA et al. Arterial baroreflex regulation of blood pressure in patients with congestive heart failure. J Am Coll Cardiol 1994;23:401-5.
105. Marin-Neto JA et al. Abnormal baroreflex control of heart rate in decompensated congestive heart failure and reversal after compensation. Am J Cardiol 1991;67: 604-10.
106. Fan W et al. Graded and dynamicreflex summationofmyelinated and unmyelinated rat aortic baroreceptors. Am J Physiol 1999;277(Pt 2):R748-56.
107. Bisognano JD et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos pivotal trial. J Am Coll Cardiol 2011;58:765-73.
108. Tordoir JH et al. An implantable carotid sinus baroreflex activating system: surgical technique and short-term outcome fromamulti-center feasibility trial forthe treatment of resistant hypertension. Eur J Vasc Endovasc Surg 2007;33:414-21.
109. Illig KA et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg 2006;44:1213-8.
110. Scheffers IJM et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56: 1254-8.
111. Zucker IH et al. Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure. Hypertension 2007;50:904-10.
112. Sabbah HN et al. Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversalof ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 2011;4:65-70.
113. Wang M et al. Long-term baroreflex activation therapy increases the threshold for the induction of lethal ventricular arrhythmias in dogs with chronic advanced heart failure. Circulation 2008;118:S-721.
114. Wustmann K et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009;54:530-6.
115. Heusser K et al. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55:619-26.
116. Brandt MC et al. Baroreflex activation as a novel therapeutic strategy for diastolic heart failure. Clin Res Cardiol 2011;100:249-51.
117. Georgakopoulos D et al. Chronic baroreflex activation: a potential therapeutic ap-proachtoheart failure with preserved ejection fraction.JCard Fail2011;17:167-78.
118. Vatner DE et al. Physiological and biochemical evidence for coordinate increases in muscarinic receptors and Gi during pacing-induced heart failure. Circulation 1996; 94:102-7.
119. Bibevski S et al. Ganglionic mechanisms contribute to diminished vagal control in heart failure. Circulation 1999;99:2958-63.
120. Bibevski S et al. Prevention of diminished parasympathetic control of the heart in experimental heart failure. Am J Physiol Heart Circ Physiol 2004;287:H1780-5.
121. Vanoli E et al. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-81.
122. Li M et al. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 2004;109:120-4.
123. Zheng C et al. Vagal stimulation markedly suppresses arrhythmias in conscious rats with chronic heart failure after myocardial infarction. Conf Proc IEEE Eng Med Biol Soc 2005;7:7072-5.
124. Sabbah HN. Electrical vagus nerve stimulation for the treatment of chronic heart failure. Cleve Clin J Med 2011;78(Suppl 1):S24-9.
125. Zhang Y et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progressionin acanine high-rate pacing model. Circ Heart Fail 2009;2:692-9.
126. Prystowsky EN et al. Effect of autonomic blockade on ventricular refractoriness and atrioventricular nodal conduction in humans. Evidence supporting a direct cholinergic action on ventricular muscle refractoriness. Circ Res 1981;49: 511-8.
127. Litovsky SH et al. Differences in the electrophysiological response of canine ventricular subendocardium and subepicardium to acetylcholine and iso-proterenol. A direct effect of acetylcholine in ventricular myocardium. Circ Res 1990;67:615-27.
128. Ng GA et al. Autonomic modulation of electrical restitution, alternans and ventricular fibrillation initiation in the isolated heart. Cardiovasc Res 2007;73:750-60.
129. Böhm M et al.; SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-94.
130. Borovikova LV et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-62.
131. De Ferrari GM et al.; for the Cardio Fit Multicenter Trial Investigators. Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 2011;32:847-55.
132. Schwartz PJ et al. Vagal stimulation for heart failure: background and first in-man study. Heart Rhythm 2009;6(Suppl):S76-81.
133. De Ferrari GM et al. Vagus nerve stimulation: from pre-clinical to clinical application: challenges and future directions. Heart Fail Rev 2011;16:195-203.
134. Schauerte P et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 2000;102:2774-80.
135. Zhang Y et al. Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: therapeutic intensities do not increase arrhythmogenesis. Heart Rhythm 2009;6:244-50.
136. Hoffmann HHet al. The numbersofnerve fibers in the vagus nerve ofman. Anat Rec 1961;139:429-35.
137. Camilleri M et al. Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device. Surgery 2008;143:723-31.
138. Gil K et al. Electrical vagus nerve stimulation decreases food consumption and weight gain in rats fed a high-fat diet. J Physiol Pharmacol 2011;62:637-46.
139. Mortara A et al. Arterial baroreflex modulationofheart rateinchronic heart failure: clinical and hemodynamic correlates and prognostic implications. Circulation 1997; 96:3450-8.
140. Adamson PB et al.; In Sync III Model 8042 and Attain OTWLead Model 4193 Clinical Trial Investigators. Continuous autonomic assessment inpatients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation 2004;110:2389-94.
141. De Ferrari GM et al. Baroreflex sensitivity predicts long-term cardiovascular mortality after myocardial infarction even in patients with preserved left ventricular function. J Am Coll Cardiol 2007;50:2285-90.
142. Koplan BA et al. Heart failure decompensation and all-cause mortality inrelation to percent biventricular pacing in patients with heart failure: is a goal of 100% biven-tricular pacing necessary? J Am Coll Cardiol 2009;53:355-60.
143. Daubert JP et al.; MADIT II Investigators. Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol 2008;51:1357-65.
144. Armour JA et al. Gross and microscopic anatomy of the human intrinsic cardiac nervous system. Anat Rec 1997;247:289-98.
145. Schauerte P et al. Catheter stimulation of cardiac parasympathetic nerves in humans: a novel approach to the cardiac autonomic nervous system. Circulation 2001;104:2430-5.
146. Zhang Y et al. Chronic atrioventricular nodal vagal stimulation: first evidence for long-term ventricular rate control in canine atrial fibrillation model. Circulation 2005;112:2904-11.
147. Mischke K et al. Chronic augmentation of the parasympathetic tone to the atrioventricular node: a non-thoracotomy neurostimulation technique for ventricular rate control during atrial fibrillation. J Cardiovasc Electrophysiol 2010; 21:193-9.
148. Zhuang S et al. Ventricular rate control by selective vagal stimulation is superior to rhythm regularization by atrioventricular nodal ablation and pacing during atrial fibrillation. Circulation 2002;106:1853-8.
149. Bianchi S et al. Atrioventricular (AV) node vagal stimulation by transvenous permanent lead implantation to modulate AV node function: safety and feasibility in humans. Heart Rhythm 2009:1282-6.
150. Castoro MA et al. Excitation properties of the right cervical vagus nerve in adult dogs. Exp Neurol 2011;227:62-8. (EPUB 2010 Sep. 17).
151. Soós P et al. Determinants and effects of electrical stimulationofthe inferior intera-trial parasympathetic plexus during atrialfibrillation.J Cardiovasc Electrophysiol 2005; 16:1362-7.
152. Franciolini F et al. Large-conductance calcium-activated potassium channels in neonatal rat intracardiac ganglion neurons. Pflugers Arch 2001;441:629-38.
153. Schmidli J, et al. Implantable carotid sinus electrical stimulation with the Rheos system for treatment of drug resistant hypertension: early clinical demonstration of safety and effectiveness from a multicenter trial Switzerland. Vascular 2006; 14: S1. XX.3 S92 Presented at VEITHsymposium, 17 Nov. 2006.
154. De Ferrari GM et al. Chronic vagal stimulation in patients with congestive heart failure. Conf Proc IEEE Eng Med Biol Soc 2009;2009:2037-9.
155. Kornet L et al. Stimulation of the intra-cardiac vagal nerves innervating the AV-node to control ventricular rate during AF: specificity, parameter optimization and chronic use up to 3 months. J Interv Card Electrophysiol 2012;33:7-18.
156. Vuckovic A et al. A comparative study of three techniques for diameter selective fiber activation in the vagal nerve: anodal block, depolarizing prepulses and slowly rising pulses. J Neural Eng 2008;5:275-86.
157. Anholt TA et al. Recruitment and blocking properties of the Cardio Fit stimulation lead. J Neural Eng 2011;8:034004.
158. Klersy C et al. A meta-analysis of remote monitoring of heart failure patients. J Am Coll Cardiol 2009;54:1683-94.
159. Kohler F et al. Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled intervention trial investigating the input of telemedicine on mortality in ambulatory patients with chronic heart failure. Circulation 2010; 122:2224 (abstract 21835).
160. Chaudhry SI et al. Telemonitoring in patients with heart failure. N Engl J Med 2010; 363:2301-9.
161. Abraham WT et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest Heart Fail 2011;17:51-5.
162. Vollmann D et al. Clinical utility of intrathoracic impedance monitoring to alert patients with an implanted device of deteriorating chronic heart failure. Eur Heart J 2007;28:1835-40.
163. Abraham WT. Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. Europace 2013;15 Suppl 1:i40-i46.
164. Whellan DJ et al. Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Programto Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients with Heart Failure) study. J Am Coll Cardiol 2010;55: 1803-10.
165. Sack S et al. Potential value of automated daily screening of cardiac resynchroniza-tion therapy defibrillator diagnostics for predictionof major cardiovascular events: results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) study. Eur J Heart Fail 2011;13:1019-27.
166. Steinhaus D et al. Implant experience with an implantable hemodynamic monitor for the management of symptomatic heart failure. Pacing Clin Electrophysiol 2005; 28:747-53.
167. Ohlsson A et al. Monitoring of pulmonary arterial diastolic pressure througharight ventricular pressure transducer. J Card Fail 1995;1:161-8.
168. Magalski A et al. Continuous ambulatory right heart pressure measurements with an implantable hemodynamic monitor: a multicenter, 12-month follow-up study of patients with chronic heart failure. J Card Fail 2002;8:63-70.
169. Adamson PB et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41:565-71.
170. Bourge RC et al. Randomized controlled trial of an implantable continuous hemo-dynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol 2008;51:1073-9.
171. Adamson PB et al. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients with Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail 2011;17:248-54.
172. Whellan DJ et al. Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. Prog Cardiovasc Dis 2011;54:107-14.
173. Merchant FM et al. Implantable sensors for heart failure. Circ Arrhythm Electrophysiol 2010;3:657-67.
174. Yu CM et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation 2005;112:841-8.
175. Troughton RW et al. Direct left atrial pressure monitoring in severe heart failure: long-term sensor performance. J Cardiovasc Transplant Res 2011;4: 3-13.
176. Ritzema J et al. Direct left atrial pressure monitoring in ambulatory heart failure patients: initial experience with a new permanent implantable device. Circulation 2007;116:2952-9.
177. Ritzema J et al. Physician-directed patient self-management of left atrial pressure in advanced chronic heart failure. Circulation 2010;121:1086-95.
178. Castro PF et al. A wireless pressure sensor for monitoring pulmonary artery pressure in advanced heart failure: initial experience. J Heart Lung
179. Verdejo HE et al. Comparison of a radiofrequency-based wireless pressure sensor to swan-ganz catheter and echocardiography for ambulatory assessment of pulmonary artery pressure in heart failure. J Am Coll Cardiol 2007;50:2375-82.
180. Abraham WT et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011;377:658-66.